The current state of adverse event reporting in hemophilia

被引:2
作者
van Vulpen, Lize F. D. [1 ,2 ]
Saccullo, Giorgia [1 ]
Iorio, Alfonso [3 ]
Makris, Michael [1 ,4 ]
机构
[1] Royal Hallamshire Hosp, Sheffield Haemophilia & Thrombosis Ctr, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England
[2] Univ Med Ctr Utrecht, Van Creveldklin, Utrecht, Netherlands
[3] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[4] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England
关键词
Bleeding disorders; haemophilia; safety; surveillance; concentrate; RECOMBINANT FACTOR-VIII; HEPATITIS-C VIRUS; INHIBITOR DEVELOPMENT; SAFETY SURVEILLANCE; BLEEDING DISORDERS; UNITED-KINGDOM; A PATIENTS; CHILDREN; LIFE; PRODUCTS;
D O I
10.1080/17474086.2017.1272410
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Replacement of the missing clotting factor is the mainstay of hemophilia treatment. Whilst historically many hemophilia patients were infected with blood-borne viruses transmitted via plasma-derived products, nowadays the formation of alloantibodies against the missing clotting factor is the main adverse event of treatment.Areas covered: This paper provides an overview of the current national and international adverse event reporting systems, what these surveillance schemes taught us about side effects of the products presently in use, and elaborates on how to adapt these systems to the challenges we face with the changing treatment landscape.Expert commentary: Treatment of inherited bleeding disorders was accompanied by severe complications in the past, resulting in major morbidity and mortality. Current products are much safer, but still require monitoring via efficient safety surveillance systems. Adverse events are reported in national and international systems. With many new products entering the market, as well as non-factor replacement therapies, new safety issues may arise. It is important to identify potential adverse events early by making surveillance systems suitable to pick up unknown or unexpected effects, and to recognize and communicate patterns of adverse events rapidly.
引用
收藏
页码:161 / 168
页数:8
相关论文
共 73 条
  • [11] Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding: a report from the SeveNBleeP registry
    Blatny, Jan
    Mathew, Prasad
    Monagle, Paul
    Ovesna, Petra
    Fiamoli, Veronika
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2014, 25 (04) : 326 - 332
  • [12] Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A
    Calvez, Thierry
    Chambost, Herve
    Claeyssens-Donadel, Segolene
    d'Oiron, Roseline
    Goulet, Veronique
    Guillet, Benoit
    Heritier, Virginie
    Milien, Vanessa
    Rothschild, Chantal
    Roussel-Robert, Valerie
    Vinciguerra, Christine
    Goudemand, Jenny
    [J]. BLOOD, 2014, 124 (23) : 3398 - 3408
  • [13] Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006)
    Chitlur, M.
    Warrier, I.
    Rajpurkar, M.
    Lusher, J. M.
    [J]. HAEMOPHILIA, 2009, 15 (05) : 1027 - 1031
  • [14] Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
    Chowdary, P.
    Lethagen, S.
    Friedrich, U.
    Brand, B.
    Hay, C.
    Karim, F. Abdul
    Klamroth, R.
    Knoebl, P.
    Laffan, M.
    Mahlangu, J.
    Miesbach, W.
    Nielsen, J. Dalsgaard
    Martin-Salces, M.
    Angchaisuksiri, P.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (05) : 743 - 754
  • [15] Similar bleeding phenotype in young children with haemophilia A or B: a cohort study
    Clausen, N.
    Petrini, P.
    Claeyssens-Donadel, S.
    Gouw, S. C.
    Liesner, R.
    [J]. HAEMOPHILIA, 2014, 20 (06) : 747 - 755
  • [16] The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO
    Collins, P.
    Chalmers, E.
    Chowdary, P.
    Keeling, D.
    Mathias, M.
    O'Donnell, J.
    Pasi, K. J.
    Rangarajan, S.
    Thomas, A.
    [J]. HAEMOPHILIA, 2016, 22 (04) : 487 - 498
  • [17] Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011
    Collins, Peter W.
    Palmer, Benedict P.
    Chalmers, Elizabeth A.
    Hart, Daniel P.
    Liesner, Ri
    Rangarajan, Savita
    Talks, Katherine
    Williams, Michael
    Hay, Charles R. M.
    [J]. BLOOD, 2014, 124 (23) : 3389 - 3397
  • [18] Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies
    Coppola, A.
    Franchini, M.
    Makris, M.
    Santagostino, E.
    Di Minno, G.
    Mannucci, P. M.
    [J]. HAEMOPHILIA, 2012, 18 (03) : e173 - e187
  • [19] Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV
    Darby, Sarah C.
    Kan, Sau Wan
    Spooner, Rosemary J.
    Giangrande, Paul L. F.
    Hill, Frank G. H.
    Hay, Charles R. M.
    Lee, Christine A.
    Ludlam, Christopher A.
    Williams, Michael
    [J]. BLOOD, 2007, 110 (03) : 815 - 825
  • [20] International workshop on immune tolerance induction: consensus recommendations
    Dimichele, D. M.
    Hoots, W. K.
    Pipe, S. W.
    Rivard, G. E.
    Santagostino, E.
    [J]. HAEMOPHILIA, 2007, 13 : 1 - 22